Pro Football Player Says His Lymphoma is in Remission
John McClain, who covers the NFL for the Houston Chronicle, is reporting that Houston Texans offensive lineman David Quessenberry is in remission from non-Hodgkin's lymphoma.
Having finished radiation treatment, he is still undergoing monthly chemotherapy maintenance. Nonetheless, Quessenberry began hitting the weight room at NRG Stadium last week in an attempt to put on some of the weight he lost during treatment.
"I'm getting my body back up," he told McClain, saying he was hoping to be around 300 lbs. "I'm up to 275-278. I used to think lifting weights was a pain in the butt, but now I love every single minute of it. It's awesome."
Quessenberry was diagnosed during training camp last year
Quessenberry was drafted out of San Jose State in 2013 in the sixth round. Last year he was preparing to try out for a starting job with the Texans when he received his diagnosis.
Source: Houston Chronicle
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
